Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of Granulocyte Infusion for Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04124666
Recruitment Status : Not yet recruiting
First Posted : October 11, 2019
Last Update Posted : October 11, 2019
Sponsor:
Information provided by (Responsible Party):
Shanghai East Hospital

Brief Summary:

Background & Rationale:

For years, most tumor immunotherapy researches have focused on T cell and natural killer (NK) cell therapies, most of which involve amplification and modification of the patient's immune cells for reinfusion therapy. However, for the treatment of solid tumors, there is currently little breakthrough. Recently, researchers have reported a colony of cancer-resistant mice developed from a single mouse that was immune to multiple lethal cancer cell injections. Further research revealed that such anti-cancer immunity can cause rapid shrinkage or disappearance of the tumors in other cancer-bearing mice. Interestingly, this therapeutic effect is due to the donor granulocytes, instead of T cells or NK cells. Infusion of granulocytes is a classic therapy in treating infection associated with granulocytopenia. Currently, clinical collection of blood components, including isolation of granulocytes, is a mature technique. The infusion of granulocytes is a viable anticancer therapy combining the classic technique and novel anticancer approach. This proposed trial will test whether granulocyte infusions from healthy unrelated donors can be used to treat advanced cancer. In the proposed trial, up to 100 Subjects with advanced cancer can be entered. Each patient will be given a dose of (2.0-5.0)x10^10 granulocytes from a different healthy donor every week over a course of 5 doses. The trial will evaluate the subject's cancer 7, 30, 90 and 180 days after the last infusion.


Condition or disease Intervention/treatment Phase
Advanced Cancer Biological: Granulocytes Phase 1 Phase 2

Detailed Description:
Granulocyte anti-cancer therapy refers to a method in which healthy donor granulocytes with high cancer-killing activity are collected and infused into a specific cancer patient by matching, to achieve the therapeutic anticancer effect. In this proposed trial, up to 100 Subjects with advanced cancer can be entered. Potentially hundreds of healthy Donor-participants will be recruited. First, granulocyte donors will be identified via in-vitro assay of Cancer Killing Activity (CKA), which screens healthy Donor-participants for those with anticancer activity of more than 80%. Secondly, after donor-recipient blood matching, (2.0-5.0)x10^10 granulocytes will be collected from each donor, accounting for about 1/10 of the human body. Each patient will be given a dose of (2.0-5.0)x10^10 granulocytes from a different donor per week over a course of 5 doses (with an ideal total infusion of 2X10^11 granulocytes). After each infusion, the patients will be monitored carefully for possible adverse events. If adverse events occur, the infusion can be slowed down or stopped until the adverse events can be managed. The trial will observe the subject's cancer 7, 30, 90 and 180 days after the last infusion. Target lesions, non-target lesions, and new lesions will be evaluated via medical imaging and tumor markers. The responses will be compared against the measurements at baseline.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study of Allogeneic Granulocyte Infusion in the Treatment of Patients With Advanced Cancer
Estimated Study Start Date : October 1, 2019
Estimated Primary Completion Date : September 30, 2022
Estimated Study Completion Date : September 30, 2022

Arm Intervention/treatment
Experimental: Granulocytes infusion only
Fresh, non-irradiated granulocytes from ABO, Rh, CMV compatible, unrelated donors; bioactivity of anti-cancer ability meets the criteria.
Biological: Granulocytes
Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.




Primary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: 90 days post treatment ]
    The trial will observe the subject's progression free survival for 3 months after the granulocyte infusions are completed.


Secondary Outcome Measures :
  1. median Overall Survival (mOS) [ Time Frame: 180 days post treatment ]
    The patients will be followed 1 week, 1 month, 3 months and 6 months after the last treatment. Median Overall Survival will be measured as the length of time from the date of inclusion that half of the patients are still alive.

  2. Objective Response Rate (ORR ) [ Time Frame: 180 days post treatment ]
    Objective Response Rate will be evaluated based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. If a response is achieved in a patient, the evaluation will be repeated 4-6 weeks after the first evaluation to confirm the response.

  3. Disease Control Rate (DCR) [ Time Frame: 180 days post treatment ]
    Disease Control Rate will be measured as the percentage of patients achieved complete response (CR), partial response (PR) and stable disease (SD) to the treatment (evaluated based on RECIST 1.1).

  4. Quality of life measured in ECOG [ Time Frame: 180 days post treatment ]
    ECOG Scale of Performance Status will be evaluated for patients after treatment to reflect impact on quality of life.

  5. Treatment-related adverse events [ Time Frame: 5 weeks of treatment and 1 month post treatment ]
    Incidence of treatment-related adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria for Subjects:

  • Malignant tumor confirmed by puncture pathology/postoperative pathology;
  • Clinical stage IV;
  • Performance status of ≤2 on the ECOG scale
  • Life expectancy of at least 3 months
  • All patients was diagnosed metastatic tumor by histology and cytology. Cytoreductive surgery can be performed if the patient can endure surgery.
  • Measurable Disease: Lesions that can be accurately measured in at least one dimension (longest diameter recorded) as 20 mm with conventional technique or as 10 mm with spiral CT scan.If the lesion is between 15mm and 20mm, the thickness of the CT layer should be no more than 0.5mm. For multiple lesions, select a representative 10 lesions (maximum 5 in the same organ) and calculate the sum of the longest diameters of all target lesions as the baseline sum diameter.
  • ≥ 4 weeks since prior medical therapy, radiation therapy, and surgery
  • Laboratory tests meet the following criteria:

A. Bone marrow function: Absolute blood neutrophil (ANC) count ≥1*10^9 /L, blood small (PLT) ≥75*10^9 /L.

B. Liver function: serum total bilirubin (STB), combined bilirubin (CB) ≤ upper limit of normal (ULN) * 1.5, alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN*2.5 (in the absence of liver metastases), or ≤ULN*5 (with liver metastases);

C. Renal function: serum creatinine (Cr) ≤ ULN * 1.5, endogenous creatinine clearance (Ccr) ≥ 50 mL / min (calculated using the Cockcroft-Gault formula, see Appendix 2);

  • The anti-neutrophil antibody test result was negative.
  • The patient volunteered and signed an informed consent form.

Exclusion Criteria of Subjects:

  • Arrhythmia, congestive heart failure, or severe coronary artery disease;
  • Pregnant or nursing women;
  • Patients with severe autoimmune diseases;
  • Patients who have been using or are using immunosuppressive agents for a long time;
  • Those with coagulopathy;
  • Cases that the investigator considered inappropriate for inclusion.

Inclusion Criteria for Granulocyte Donors:

  • Must have signed Donor-participant Informed Consent Form
  • Must be able to provide granulocytes in local blood donation center, and transport collected granulocytes to the hospital blood bank or clinical application within 24 hours;
  • Must score >80% in Cancer Killing Assay (CKA), a score of 60-80% would be considered when there are insufficient donors;
  • Must have CMV negative or positive sero-testing completed; only seronegative donors are accepted for a seronegative recipient;
  • Must have compatible ABO and RH typing with the recipient;
  • Must be qualified for blood donation: aged 18-35, male >50kg or female >45kg, normal cardiopulmonary function, specific gravity of blood male≥1.052 or female≥1.051, HbsAg, anti-HCV, anti-HIV, or syphilis tests.

Exclusion Criteria for Granulocyte Donors:

  • Dental or other minor surgery within preceding 15 days;
  • Arrhythmia, congestive heart failure, or severe coronary artery disease;
  • Major surgery within preceding 6 months;
  • Appendectomy, hernia repair, or tonsillectomy within preceding 3 months;
  • Females 3 days before or after menstruation, ≤6 months since prior pregnancy or abortion, ≤ 1 year since delivery/breastfeeding;
  • Recovery from flu or acute gastroenteritis within preceding week, acute renal infection within preceding month, pneumonia within preceding 3 months;
  • Recovery from infectious diseases such as dysentery within preceding 6 months, typhoid fever within preceding year, brucellosis within preceding 2 years, or malaria within preceding 3 years;
  • Recovery from localized dermatitis within preceding week, extensive inflammation within preceding 2 weeks;
  • Receiving whole blood or blood components within preceding 5 years;
  • Allergic to G-CSF mobilizer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04124666


Contacts
Layout table for location contacts
Contact: Wenjun Le, Ph.D (+86)-21-38804518 wenjunle@tongji.edu.cn
Contact: Zhongming Liu, MD/Ph.D (+86)-21-38804518 liu.zhongmin@tongji.edu.cn

Sponsors and Collaborators
Shanghai East Hospital
Investigators
Layout table for investigator information
Principal Investigator: Zhongming Liu, MD/Ph.D Shanghai East Hospital, Shanghai Tongji University

Layout table for additonal information
Responsible Party: Shanghai East Hospital
ClinicalTrials.gov Identifier: NCT04124666     History of Changes
Other Study ID Numbers: KY2019-01
First Posted: October 11, 2019    Key Record Dates
Last Update Posted: October 11, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms